Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb 21;82(6):1233–1238. doi: 10.1054/bjoc.1999.1068

Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases

D G Jayne 1, S L Perry 1, E Morrison 1, S M Farmery 1, P J Guillou 1
PMCID: PMC2363354  PMID: 10735511

Abstract

Curative surgery for gastrointestinal malignancy is commonly thwarted by local tumour recurrence. The heparin-binding growth factors, basic fibroblast growth factor (bFGF), heparin-binding epidermal growth factor-like growth factor (HB-EGF) and vascular epidermal growth factor (VEGF) are all implicated in the metastatic process, but whether or not these essential growth factors are produced by the activated peritoneum is unknown. This study reveals that peritoneal mesothelial cells constitutively express mRNA for bFGF, HB-EGF and two VEGF spliced variants, VEGF121and VEGF165. Mesothelial activation with interleukin (IL)-1b or tumour necrosis factor (TNF)-a produced an up-regulation of mRNA for HB-EGF and VEGF, but not bFGF expression. IL-6 failed to stimulate growth factor expression, whereas IL-2 produced a marked suppression in HB-EGF and bFGF, but not VEGF expression. Mesothelial cells were shown to predominantly express mRNA for the intermediate affinity (bgc) IL-2 receptor. Cytokine-induced growth factor up-regulation was confirmed at the protein level using Western blotting of mesothelial cell lysates for HB-EGF and culture supernatant enzyme-linked immunosorbent assay for VEGF. The production of these growth factors by human mesothelial cells may play a significant role in post-operative peritoneal tumour recurrence. Their common heparin-binding property offers a potential therapeutic target for manipulating the growth factor environment of the human peritoneum. © 2000 Cancer Research Campaign

Keywords: peritoneum, mesothelial cell, cytokine, heparin-binding growth factors, tumour metastasis

Full Text

The Full Text of this article is available as a PDF (134.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badia J. M., Whawell S. A., Scott-Coombes D. M., Abel P. D., Williamson R. C., Thompson J. N. Peritoneal and systemic cytokine response to laparotomy. Br J Surg. 1996 Mar;83(3):347–348. doi: 10.1002/bjs.1800830316. [DOI] [PubMed] [Google Scholar]
  2. Chailley-Heu B., Rubio S., Rougier J. P., Ducroc R., Barlier-Mur A. M., Ronco P., Bourbon J. R. Expression of hydrophilic surfactant proteins by mesentery cells in rat and man. Biochem J. 1997 Nov 15;328(Pt 1):251–256. doi: 10.1042/bj3280251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. D'Amore P. A. Modes of FGF release in vivo and in vitro. Cancer Metastasis Rev. 1990 Nov;9(3):227–238. doi: 10.1007/BF00046362. [DOI] [PubMed] [Google Scholar]
  4. Davies N., Kapur P., Gillespie J., Guillou P. J., Poston G. J. Transforming growth factor alpha is trophic to pancreatic cancer in vivo. Gut. 1993 Aug;34(8):1097–1098. doi: 10.1136/gut.34.8.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dignass A. U., Tsunekawa S., Podolsky D. K. Fibroblast growth factors modulate intestinal epithelial cell growth and migration. Gastroenterology. 1994 May;106(5):1254–1262. doi: 10.1016/0016-5085(94)90017-5. [DOI] [PubMed] [Google Scholar]
  6. Eggermont A. M., Steller E. P., Marquet R. L., Jeekel J., Sugarbaker P. H. Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells. Cancer Detect Prev. 1988;12(1-6):421–429. [PubMed] [Google Scholar]
  7. Fukasawa M., Yanagihara D. L., Rodgers K. E., DiZerega G. S. The mitogenic activity of peritoneal tissue repair cells: control by growth factors. J Surg Res. 1989 Jul;47(1):45–51. doi: 10.1016/0022-4804(89)90046-2. [DOI] [PubMed] [Google Scholar]
  8. Gillespie J., Dye J. F., Schachter M., Guillou P. J. Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Br J Cancer. 1993 Dec;68(6):1122–1126. doi: 10.1038/bjc.1993.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein D. S., Lu M. L., Hattori T., Ratliff T. L., Loughlin K. R., Kavoussi L. R. Inhibition of peritoneal tumor-cell implantation: model for laparoscopic cancer surgery. J Endourol. 1993 Jun;7(3):237–241. doi: 10.1089/end.1993.7.237. [DOI] [PubMed] [Google Scholar]
  10. Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991 Dec;5(12):1806–1814. doi: 10.1210/mend-5-12-1806. [DOI] [PubMed] [Google Scholar]
  11. Iida S., Katoh O., Tokunaga A., Terada M. Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1113–1119. doi: 10.1006/bbrc.1994.1346. [DOI] [PubMed] [Google Scholar]
  12. Jayson G. C., Gallagher J. T. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer. 1997;75(1):9–16. doi: 10.1038/bjc.1997.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kinnaert P., De Wilde J. P., Bournonville B., Husson C., Salmon I. Direct activation of human peritoneal mesothelial cells by heat-killed microorganisms. Ann Surg. 1996 Dec;224(6):749–755. doi: 10.1097/00000658-199612000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klein C. L., Bittinger F., Skarke C. C., Wagner M., Köhler H., Walgenbach S., Kirkpatrick C. J. Effects of cytokines on the expression of cell adhesion molecules by cultured human omental mesothelial cells. Pathobiology. 1995;63(4):204–212. doi: 10.1159/000163953. [DOI] [PubMed] [Google Scholar]
  15. Kobrin M. S., Funatomi H., Friess H., Buchler M. W., Stathis P., Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1705–1709. doi: 10.1006/bbrc.1994.2131. [DOI] [PubMed] [Google Scholar]
  16. Ku P. T., D'Amore P. A. Regulation of basic fibroblast growth factor (bFGF) gene and protein expression following its release from sublethally injured endothelial cells. J Cell Biochem. 1995 Jul;58(3):328–343. doi: 10.1002/jcb.240580307. [DOI] [PubMed] [Google Scholar]
  17. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  18. Lanfrancone L., Boraschi D., Ghiara P., Falini B., Grignani F., Peri G., Mantovani A., Pelicci P. G. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. Blood. 1992 Dec 1;80(11):2835–2842. [PubMed] [Google Scholar]
  19. Melder R. J., Koenig G. C., Witwer B. P., Safabakhsh N., Munn L. L., Jain R. K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996 Sep;2(9):992–997. doi: 10.1038/nm0996-992. [DOI] [PubMed] [Google Scholar]
  20. Miyoshi E., Higashiyama S., Nakagawa T., Hayashi N., Taniguchi N. Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line. J Biol Chem. 1997 May 30;272(22):14349–14355. doi: 10.1074/jbc.272.22.14349. [DOI] [PubMed] [Google Scholar]
  21. Montesano R. 1992 Mack Forster Award Lecture. Review. Regulation of angiogenesis in vitro. Eur J Clin Invest. 1992 Aug;22(8):504–515. doi: 10.1111/j.1365-2362.1992.tb01498.x. [DOI] [PubMed] [Google Scholar]
  22. Naef M., Yokoyama M., Friess H., Büchler M. W., Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer. 1996 May 3;66(3):315–321. doi: 10.1002/(SICI)1097-0215(19960503)66:3<315::AID-IJC8>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  23. Narita T., Kawakami-Kimura N., Sato M., Matsuura N., Higashiyama S., Taniguchi N., Kannagi R. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. Oncology. 1996 Sep-Oct;53(5):374–381. doi: 10.1159/000227591. [DOI] [PubMed] [Google Scholar]
  24. Ottow R. T., Eggermont A. M., Steller E. P., Sugarbaker P. H. The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells. Cancer. 1987 Oct 1;60(7):1465–1473. doi: 10.1002/1097-0142(19871001)60:7<1465::aid-cncr2820600711>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  25. Pepper M. S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992 Dec 15;189(2):824–831. doi: 10.1016/0006-291x(92)92277-5. [DOI] [PubMed] [Google Scholar]
  26. Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastasis. Cancer Metastasis Rev. 1993 Sep;12(3-4):345–361. doi: 10.1007/BF00665962. [DOI] [PubMed] [Google Scholar]
  27. Radinsky R., Risin S., Fan D., Dong Z., Bielenberg D., Bucana C. D., Fidler I. J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res. 1995 Jan;1(1):19–31. [PubMed] [Google Scholar]
  28. Rapraeger A. C., Guimond S., Krufka A., Olwin B. B. Regulation by heparan sulfate in fibroblast growth factor signaling. Methods Enzymol. 1994;245:219–240. doi: 10.1016/0076-6879(94)45013-7. [DOI] [PubMed] [Google Scholar]
  29. Rapraeger A. C., Krufka A., Olwin B. B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 1991 Jun 21;252(5013):1705–1708. doi: 10.1126/science.1646484. [DOI] [PubMed] [Google Scholar]
  30. Sato M., Narita T., Kawakami-Kimura N., Higashiyama S., Taniguchi N., Akiyama S., Hashimoto T., Manabe T., Kannagi R. Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cells. Cancer Lett. 1996 Apr 19;102(1-2):183–191. doi: 10.1016/0304-3835(96)04158-4. [DOI] [PubMed] [Google Scholar]
  31. Sironi M., Sciacca F. L., Matteucci C., Conni M., Vecchi A., Bernasconi S., Minty A., Caput D., Ferrara P., Colotta F. Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood. 1994 Sep 15;84(6):1913–1921. [PubMed] [Google Scholar]
  32. Soker S., Fidder H., Neufeld G., Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem. 1996 Mar 8;271(10):5761–5767. doi: 10.1074/jbc.271.10.5761. [DOI] [PubMed] [Google Scholar]
  33. Soker S., Takashima S., Miao H. Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998 Mar 20;92(6):735–745. doi: 10.1016/s0092-8674(00)81402-6. [DOI] [PubMed] [Google Scholar]
  34. Stylianou E., Jenner L. A., Davies M., Coles G. A., Williams J. D. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 1990 Jun;37(6):1563–1570. doi: 10.1038/ki.1990.150. [DOI] [PubMed] [Google Scholar]
  35. Tokunaga A., Onda M., Okuda T., Teramoto T., Fujita I., Mizutani T., Kiyama T., Yoshiyuki T., Nishi K., Matsukura N. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer. 1995 Mar 15;75(6 Suppl):1418–1425. doi: 10.1002/1097-0142(19950315)75:6+<1418::aid-cncr2820751505>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  36. Topley N., Mackenzie R. K., Williams J. D. Macrophages and mesothelial cells in bacterial peritonitis. Immunobiology. 1996 Oct;195(4-5):563–573. doi: 10.1016/S0171-2985(96)80022-2. [DOI] [PubMed] [Google Scholar]
  37. Ushiro S., Ono M., Izumi H., Kohno K., Taniguchi N., Higashiyama S., Kuwano M. Heparin-binding epidermal growth factor-like growth factor: p91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Jpn J Cancer Res. 1996 Jan;87(1):68–77. doi: 10.1111/j.1349-7006.1996.tb00202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES